<it>Ex vivo </it>activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of <it>Plasmodium falciparum</it>

<p>Abstract</p> <p>Background</p> <p>The aim of the present work was to assess i) <it>ex vivo </it>activity of pyronaridine (PND) and piperaquine (PPQ), as new components of artemisinin-based combination therapy (ACT), to define susceptibility baseline, ii)...

Full description

Bibliographic Details
Main Authors: Pascual Aurélie, Parola Philippe, Benoit-Vical Françoise, Simon Fabrice, Malvy Denis, Picot Stéphane, Delaunay Pascal, Basset Didier, Maubon Danièle, Faugère Bernard, Ménard Guillaume, Bourgeois Nathalie, Oeuvray Claude, Didillon Eric, Rogier Christophe, Pradines Bruno
Format: Article
Language:English
Published: BMC 2012-02-01
Series:Malaria Journal
Subjects:
Online Access:http://www.malariajournal.com/content/11/1/45
id doaj-9ec13234059144b18c4e63182e29403b
record_format Article
spelling doaj-9ec13234059144b18c4e63182e29403b2020-11-25T01:02:59ZengBMCMalaria Journal1475-28752012-02-011114510.1186/1475-2875-11-45<it>Ex vivo </it>activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of <it>Plasmodium falciparum</it>Pascual AurélieParola PhilippeBenoit-Vical FrançoiseSimon FabriceMalvy DenisPicot StéphaneDelaunay PascalBasset DidierMaubon DanièleFaugère BernardMénard GuillaumeBourgeois NathalieOeuvray ClaudeDidillon EricRogier ChristophePradines Bruno<p>Abstract</p> <p>Background</p> <p>The aim of the present work was to assess i) <it>ex vivo </it>activity of pyronaridine (PND) and piperaquine (PPQ), as new components of artemisinin-based combination therapy (ACT), to define susceptibility baseline, ii) their activities compared to other partner drugs, namely monodesethylamodiaquine (MDAQ), lumefantrine (LMF), mefloquine (MQ), artesunate (AS) and dihydroartemisinin (DHA) against 181 <it>Plasmodium falciparum </it>isolates from African countries, India and Thailand, and iii) <it>in vitro </it>cross-resistance with other quinoline drugs, chloroquine (CQ) or quinine (QN).</p> <p>Methods</p> <p>The susceptibility of the 181 <it>P. falciparum </it>isolates to the nine anti-malarial drugs was assessed using the standard 42-hours <sup>3</sup>H-hypoxanthine uptake inhibition method.</p> <p>Results</p> <p>The IC<sub>50 </sub>values for PND ranged from 0.55 to 80.0 nM (geometric mean = 19.9 nM) and from 11.8 to 217.3 nM for PPQ (geometric mean = 66.8 nM). A significant positive correlation was shown between responses to PPQ and PND responses (<it>rho </it>= 0.46) and between PPQ and MDAQ (<it>rho </it>= 0.30). No significant correlation was shown between PPQ IC<sub>50 </sub>and responses to other anti-malarial drugs. A significant positive correlation was shown between responses to PND and MDAQ (<it>rho </it>= 0.37), PND and LMF (<it>rho </it>= 0.28), PND and QN (<it>rho </it>= 0.24), PND and AS (<it>rho </it>= 0.19), PND and DHA (<it>rho </it>= 0.18) and PND and CQ (<it>rho </it>= 0.16). All these coefficients of correlation are too low to suggest cross-resistance between PPQ or PND and the other drugs.</p> <p>Conclusions</p> <p>In this study, the excellent anti-malarial activity of PPQ and PND was confirmed. The absence of cross-resistance with quinolines and artemisinin derivatives is consistent with the efficacy of the combinations of PPQ and DHA or PND and AS in areas where parasites are resistant to conventional anti-malarial drugs.</p> http://www.malariajournal.com/content/11/1/45Malaria<it>Plasmodium falciparum</it>Anti-malarial<it>In vitro</it>ResistancePyronaridinePiperaquine
collection DOAJ
language English
format Article
sources DOAJ
author Pascual Aurélie
Parola Philippe
Benoit-Vical Françoise
Simon Fabrice
Malvy Denis
Picot Stéphane
Delaunay Pascal
Basset Didier
Maubon Danièle
Faugère Bernard
Ménard Guillaume
Bourgeois Nathalie
Oeuvray Claude
Didillon Eric
Rogier Christophe
Pradines Bruno
spellingShingle Pascual Aurélie
Parola Philippe
Benoit-Vical Françoise
Simon Fabrice
Malvy Denis
Picot Stéphane
Delaunay Pascal
Basset Didier
Maubon Danièle
Faugère Bernard
Ménard Guillaume
Bourgeois Nathalie
Oeuvray Claude
Didillon Eric
Rogier Christophe
Pradines Bruno
<it>Ex vivo </it>activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of <it>Plasmodium falciparum</it>
Malaria Journal
Malaria
<it>Plasmodium falciparum</it>
Anti-malarial
<it>In vitro</it>
Resistance
Pyronaridine
Piperaquine
author_facet Pascual Aurélie
Parola Philippe
Benoit-Vical Françoise
Simon Fabrice
Malvy Denis
Picot Stéphane
Delaunay Pascal
Basset Didier
Maubon Danièle
Faugère Bernard
Ménard Guillaume
Bourgeois Nathalie
Oeuvray Claude
Didillon Eric
Rogier Christophe
Pradines Bruno
author_sort Pascual Aurélie
title <it>Ex vivo </it>activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of <it>Plasmodium falciparum</it>
title_short <it>Ex vivo </it>activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of <it>Plasmodium falciparum</it>
title_full <it>Ex vivo </it>activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of <it>Plasmodium falciparum</it>
title_fullStr <it>Ex vivo </it>activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of <it>Plasmodium falciparum</it>
title_full_unstemmed <it>Ex vivo </it>activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of <it>Plasmodium falciparum</it>
title_sort <it>ex vivo </it>activity of the act new components pyronaridine and piperaquine in comparison with conventional act drugs against isolates of <it>plasmodium falciparum</it>
publisher BMC
series Malaria Journal
issn 1475-2875
publishDate 2012-02-01
description <p>Abstract</p> <p>Background</p> <p>The aim of the present work was to assess i) <it>ex vivo </it>activity of pyronaridine (PND) and piperaquine (PPQ), as new components of artemisinin-based combination therapy (ACT), to define susceptibility baseline, ii) their activities compared to other partner drugs, namely monodesethylamodiaquine (MDAQ), lumefantrine (LMF), mefloquine (MQ), artesunate (AS) and dihydroartemisinin (DHA) against 181 <it>Plasmodium falciparum </it>isolates from African countries, India and Thailand, and iii) <it>in vitro </it>cross-resistance with other quinoline drugs, chloroquine (CQ) or quinine (QN).</p> <p>Methods</p> <p>The susceptibility of the 181 <it>P. falciparum </it>isolates to the nine anti-malarial drugs was assessed using the standard 42-hours <sup>3</sup>H-hypoxanthine uptake inhibition method.</p> <p>Results</p> <p>The IC<sub>50 </sub>values for PND ranged from 0.55 to 80.0 nM (geometric mean = 19.9 nM) and from 11.8 to 217.3 nM for PPQ (geometric mean = 66.8 nM). A significant positive correlation was shown between responses to PPQ and PND responses (<it>rho </it>= 0.46) and between PPQ and MDAQ (<it>rho </it>= 0.30). No significant correlation was shown between PPQ IC<sub>50 </sub>and responses to other anti-malarial drugs. A significant positive correlation was shown between responses to PND and MDAQ (<it>rho </it>= 0.37), PND and LMF (<it>rho </it>= 0.28), PND and QN (<it>rho </it>= 0.24), PND and AS (<it>rho </it>= 0.19), PND and DHA (<it>rho </it>= 0.18) and PND and CQ (<it>rho </it>= 0.16). All these coefficients of correlation are too low to suggest cross-resistance between PPQ or PND and the other drugs.</p> <p>Conclusions</p> <p>In this study, the excellent anti-malarial activity of PPQ and PND was confirmed. The absence of cross-resistance with quinolines and artemisinin derivatives is consistent with the efficacy of the combinations of PPQ and DHA or PND and AS in areas where parasites are resistant to conventional anti-malarial drugs.</p>
topic Malaria
<it>Plasmodium falciparum</it>
Anti-malarial
<it>In vitro</it>
Resistance
Pyronaridine
Piperaquine
url http://www.malariajournal.com/content/11/1/45
work_keys_str_mv AT pascualaurelie itexvivoitactivityoftheactnewcomponentspyronaridineandpiperaquineincomparisonwithconventionalactdrugsagainstisolatesofitplasmodiumfalciparumit
AT parolaphilippe itexvivoitactivityoftheactnewcomponentspyronaridineandpiperaquineincomparisonwithconventionalactdrugsagainstisolatesofitplasmodiumfalciparumit
AT benoitvicalfrancoise itexvivoitactivityoftheactnewcomponentspyronaridineandpiperaquineincomparisonwithconventionalactdrugsagainstisolatesofitplasmodiumfalciparumit
AT simonfabrice itexvivoitactivityoftheactnewcomponentspyronaridineandpiperaquineincomparisonwithconventionalactdrugsagainstisolatesofitplasmodiumfalciparumit
AT malvydenis itexvivoitactivityoftheactnewcomponentspyronaridineandpiperaquineincomparisonwithconventionalactdrugsagainstisolatesofitplasmodiumfalciparumit
AT picotstephane itexvivoitactivityoftheactnewcomponentspyronaridineandpiperaquineincomparisonwithconventionalactdrugsagainstisolatesofitplasmodiumfalciparumit
AT delaunaypascal itexvivoitactivityoftheactnewcomponentspyronaridineandpiperaquineincomparisonwithconventionalactdrugsagainstisolatesofitplasmodiumfalciparumit
AT bassetdidier itexvivoitactivityoftheactnewcomponentspyronaridineandpiperaquineincomparisonwithconventionalactdrugsagainstisolatesofitplasmodiumfalciparumit
AT maubondaniele itexvivoitactivityoftheactnewcomponentspyronaridineandpiperaquineincomparisonwithconventionalactdrugsagainstisolatesofitplasmodiumfalciparumit
AT faugerebernard itexvivoitactivityoftheactnewcomponentspyronaridineandpiperaquineincomparisonwithconventionalactdrugsagainstisolatesofitplasmodiumfalciparumit
AT menardguillaume itexvivoitactivityoftheactnewcomponentspyronaridineandpiperaquineincomparisonwithconventionalactdrugsagainstisolatesofitplasmodiumfalciparumit
AT bourgeoisnathalie itexvivoitactivityoftheactnewcomponentspyronaridineandpiperaquineincomparisonwithconventionalactdrugsagainstisolatesofitplasmodiumfalciparumit
AT oeuvrayclaude itexvivoitactivityoftheactnewcomponentspyronaridineandpiperaquineincomparisonwithconventionalactdrugsagainstisolatesofitplasmodiumfalciparumit
AT didilloneric itexvivoitactivityoftheactnewcomponentspyronaridineandpiperaquineincomparisonwithconventionalactdrugsagainstisolatesofitplasmodiumfalciparumit
AT rogierchristophe itexvivoitactivityoftheactnewcomponentspyronaridineandpiperaquineincomparisonwithconventionalactdrugsagainstisolatesofitplasmodiumfalciparumit
AT pradinesbruno itexvivoitactivityoftheactnewcomponentspyronaridineandpiperaquineincomparisonwithconventionalactdrugsagainstisolatesofitplasmodiumfalciparumit
_version_ 1725202810999406592